Ovid Therapeutics (OVID) Cash from Financing Activities (2016 - 2026)

Ovid Therapeutics' Cash from Financing Activities history runs 11 years deep, the most recent figure standing at $89.0 million for Q1 2026.

• Quarterly Cash from Financing Activities rose 684376.92% year-over-year to $89.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $164.2 million (up 40238.08% YoY) and the FY2025 annual result came in at $75.2 million, up 11991.16% from the prior year.
• Cash from Financing Activities was $89.0 million for Q1 2026 at Ovid Therapeutics, up from $75.2 million in the prior quarter.
• Across five years, Cash from Financing Activities topped out at $89.0 million in Q1 2026 and bottomed at -$43599.0 in Q4 2022.
• A 5-year average of $13.0 million and a median of $109549.0 in 2022 frame the typical range for Cash from Financing Activities.
• Annual changes were most pronounced in 2022 — Cash from Financing Activities slumped 139.93% — and 2026, when it soared 684376.92%.
• Ovid Therapeutics' Cash from Financing Activities stood at -$43599.0 in 2022, then jumped by 68984.61% to $30.0 million in 2023, then plunged by 99.87% to $38000.0 in 2024, then surged by 197739.47% to $75.2 million in 2025, then grew by 18.36% to $89.0 million in 2026.
• Business Quant data shows OVID's Cash from Financing Activities at $89.0 million in Q1 2026, $75.2 million in Q4 2025, and $15000.0 in Q3 2025.